Merck Sharp + Dohme Corp.

Ab Sciex LLC

Watson Investor Communications, LLC

Symbol Technologies, LLC

Mehul F Patel

M Arshad Siddiqui

Yang Nan

Zhaoyang Meng

Yongxin Han

Yunfu Luo

Gerald Wayne Shipps, Jr

Christopher S Burgey

Yongqi Deng

Kenneth L Arrington

Andrew J McRiner

Lianyun Zhao

Jerome Swartz

Joseph M Katz

Neng-Yang Shih

Ronald J Doll

Chinh Tan

Vincent Stewart Madison

Alan B Cooper

Joseph Michael Kelly

Younong Yu

James J Perkins

Jian Liu

Deping Wang

Jason M Cox

Robert Sanders

Mark E Layton

Liangqin Guo

Hong Liu

Allan Perry Herrod

Chun Sing Li

Sunil Paliwal

Ronald M Kim

Alan W Hruza

Helen Y Chen

Li Xiao

Umar Faruk Mansoor

Robert James Pang

John Raymond Klein

Xiaolei Gao

Hon-Chung Tsui

Matthew H Daniels

Christopher James Bungard

Binyuan Sun

Hugh Charles Crenshaw

Michael J Kelly, Iii

Jiayi Xu

Panduranga Adulla P Reddy

Duan Liu

Amit K Mandal

Chaoyang Dai

Robert Sun

Jagdish A Desai

Altaf Mulla

Ahmed Abdi Samatar

Walter Won

Sobhana Babu Boga

David Benjamin Belanger

James J-s Wang

Ting Zhang

Iwona Wrona

Hugh Y Zhu

Patrick J Curran

Liping Yang

Liang Zhu

Hongbo Zeng

Tong Wang

Gerald W Shipps

Shuyi Tang

Cliff C Cheng

Charles A Buckner, Iii

Panduranga Adulla Reddy

Abdul-Basit Alhassan

Youhao Dong

Matthew Richards

Joshua Tanner Nevill

Azim Alan Celebi

John Lert

Angie R Angeles

Zhiyu Lei

Xin Yao

Lalanthi Dilrukshi Vitharana

Daniel M Hartmann

Cheryl E Watson

David G Tew

Subrahmanyam Gudipati

Yinyan Zhao

Brian M Eklov

Yiji Wu

Yaozong Li

Gregory A Votaw

William Karsh

Frank Anthony Montefusco

Jeffrey F Fritzen

David W Wyrick

Dawn M Schmidt

Jaume Balsells

Sara H Thrall

Robert Gilfillan

Eric Geier

Disclosed are compounds of Formula (I), Formula (II), or a salt thereof: Formula (I) Formula (II) which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula (I), Formula (II) or their salts, and methods of treating pain disorders, cough, and itch using the same.

4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels

Compounds of Formula I: are HIV reverse transcriptase inhibitors, wherein R, R, R, L, M and Z are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Non-nucleoside reverse transcriptase inhibitors

Compounds of Formula I are described: wherein Rand Rare defined herein. The compounds of Formula I are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV, and the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. 

Prodrugs of HIV reverse transcriptase inhibitors

A loose material measuring and dispensing system including a container and dispenser. The tea container serves to store the tea leaves or grounds in a storage bin prior to activation of the system. Upon activation, the dispenser measures and loads a selected amount of tea into a hopper for dispensing, such as into a waiting cup or a tea infuser. The amount of tea may be selected based upon user operation of one of a number of quantity indicating/selection buttons provided in a user interface. The container is a sealed canister, such as a bag or jug, which is preferably impermeable to light. Furthermore, the dispenser is able to operate to load a desired amount of tea (e.g. by weight), specified by the user, into the hopper. Once the desired amount of tea is loaded into the hopper, the tea may be dispensed, such as into a waiting cup or infuser below.

System and method for dispensing a measured amount of a loose material

The present invention provides Pyrazolopyrimidine Compounds of Formula (I): wherein L, T, Z, U, V, W, R, R, R, R, and m are as defined herein, and pharmaceutically acceptable salts of such Pyrazolopyrimidine Compounds. The Pyrazolopyrimidine Compounds are useful in the treatment of cancer and other diseases or disorders wherein mTOR is deregulated.

Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors

The present invention relates to certain pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidine and dipyrazolopyrimidine compounds of Formula (I) as inhibitors of mammalian Target Of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP. The compounds may be used in the treatment of cancer and other disorders where mTOR is deregulated. The present invention further provides pharmaceutical compositions comprising the pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidine or dipyrazolopyrimidine compounds.

Fused tricyclic compounds as mTOR inhibitors

The present invention provides methods for inhibiting mTOR using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with mTOR using such compounds.

Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors

Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Compounds that are ERK inhibitors

Apparatus and Method for Handling Fluids at Nano-Scale Rates. A linear displacement pump produces non-pulsatile liquid flow rates as low as the nl/mm range. The pump includes a servo motor, a gear reduction, a lead screw, a linear stage, a barrel, and a plunger extending into the barrel and coupled to the stage. A microfluidic interconnect device can be coupled to the barrel. One or more of these pumps can be disposed in a thermally controlled pump assembly that includes a pump housing, a thermally conductive body disposed in the housing and including first and second opposing sides, and a temperature regulating element such as a thermoelectric device disposed in thermal contact with the thermally conductive body on a side thereof opposite to the barrel or barrels of the pumps.

Apparatus and method for handling fluids at nano-scale rates

Methods for characterizing a biochemical reaction and analysis of reaction products by establishing continuously variable concentration gradients of one or more reagents of the biochemical reaction are provided. Methods for determining mechanism of inhibition or activation, potency of inhibition or activation, or both of an enzyme inhibitor or activator, respectively, are also provided. The continuously variable concentration gradients can be established in a microfluidic chip.

Methods for characterizing enzyme inhibitors

Growing community of inventors

Willow Grove, PA, United States of America

Mehul F Patel